1. Home
  2. ENTX vs CMCM Comparison

ENTX vs CMCM Comparison

Compare ENTX & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • CMCM
  • Stock Information
  • Founded
  • ENTX 2010
  • CMCM 2009
  • Country
  • ENTX Israel
  • CMCM China
  • Employees
  • ENTX N/A
  • CMCM N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • CMCM Computer Software: Prepackaged Software
  • Sector
  • ENTX Health Care
  • CMCM Technology
  • Exchange
  • ENTX Nasdaq
  • CMCM Nasdaq
  • Market Cap
  • ENTX 104.0M
  • CMCM 115.1M
  • IPO Year
  • ENTX 2018
  • CMCM 2014
  • Fundamental
  • Price
  • ENTX $1.86
  • CMCM $5.60
  • Analyst Decision
  • ENTX Strong Buy
  • CMCM
  • Analyst Count
  • ENTX 1
  • CMCM 0
  • Target Price
  • ENTX $10.00
  • CMCM N/A
  • AVG Volume (30 Days)
  • ENTX 40.5K
  • CMCM 54.2K
  • Earning Date
  • ENTX 08-08-2025
  • CMCM 09-12-2025
  • Dividend Yield
  • ENTX N/A
  • CMCM N/A
  • EPS Growth
  • ENTX N/A
  • CMCM N/A
  • EPS
  • ENTX N/A
  • CMCM N/A
  • Revenue
  • ENTX $223,000.00
  • CMCM $120,663,543.00
  • Revenue This Year
  • ENTX N/A
  • CMCM $14.27
  • Revenue Next Year
  • ENTX N/A
  • CMCM $39.26
  • P/E Ratio
  • ENTX N/A
  • CMCM N/A
  • Revenue Growth
  • ENTX N/A
  • CMCM 27.02
  • 52 Week Low
  • ENTX $1.41
  • CMCM $3.02
  • 52 Week High
  • ENTX $2.79
  • CMCM $6.77
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 44.39
  • CMCM 60.38
  • Support Level
  • ENTX $1.91
  • CMCM $5.63
  • Resistance Level
  • ENTX $2.04
  • CMCM $6.62
  • Average True Range (ATR)
  • ENTX 0.10
  • CMCM 0.42
  • MACD
  • ENTX 0.00
  • CMCM 0.05
  • Stochastic Oscillator
  • ENTX 37.84
  • CMCM 49.50

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.

Share on Social Networks: